$3.95
0.349.42%
At Close: -
$3.94
-0.01-0.25%
After Hours: 4:50 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Poseida Therapeutics (NASDAQ:PSTX) Stock, Analyst Ratings, Price Targets, Forecasts
Poseida Therapeutics Inc has a consensus price target of $16.6 based on the ratings of 5 analysts. The high is $24 issued by Cantor Fitzgerald on January 7, 2022. The low is $10 issued by Piper Sandler on December 11, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on July 25, 2024, May 22, 2024, and May 2, 2024, respectively. With an average price target of $20 between HC Wainwright & Co., there's an implied 407.61% upside for Poseida Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
Cantor Fitzgerald
HC Wainwright & Co.
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Poseida Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/25/2024 | Buy Now | 407.61% | HC Wainwright & Co. | Arthur He | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2024 | Buy Now | 407.61% | HC Wainwright & Co. | Arthur He | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 407.61% | HC Wainwright & Co. | Arthur He | → $20 | Reiterates | Buy → Buy | Get Alert |
| 04/22/2024 | Buy Now | 407.61% | HC Wainwright & Co. | Arthur He | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | Buy Now | 407.61% | HC Wainwright & Co. | Arthur He | → $20 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2023 | Buy Now | 153.81% | Piper Sandler | Edward Tenthoff | $8 → $10 | Maintains | Overweight | Get Alert |
| 12/11/2023 | Buy Now | 407.61% | HC Wainwright & Co. | Arthur He | $15 → $20 | Maintains | Buy | Get Alert |
| 10/10/2023 | Buy Now | 255.33% | Cantor Fitzgerald | Jennifer Kim | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 08/08/2023 | Buy Now | 280.71% | HC Wainwright & Co. | Arthur He | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | Buy Now | 280.71% | HC Wainwright & Co. | Arthur He | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 280.71% | HC Wainwright & Co. | Arthur He | → $15 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | Buy Now | 280.71% | HC Wainwright & Co. | Arthur He | → $15 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | Buy Now | 280.71% | HC Wainwright & Co. | Arthur He | → $15 | Maintains | Buy | Get Alert |
| 02/01/2023 | Buy Now | 509.14% | Cantor Fitzgerald | Jennifer Kim | → $24 | Reiterates | → Overweight | Get Alert |
| 01/04/2023 | Buy Now | 280.71% | HC Wainwright & Co. | Swayampakula Ramakanth | → $15 | Initiates | → Buy | Get Alert |
| 08/09/2022 | Buy Now | 179.19% | Piper Sandler | Edward Tenthoff | $9 → $11 | Maintains | Overweight | Get Alert |
| 05/13/2022 | Buy Now | 128.43% | Piper Sandler | Edward Tenthoff | $19 → $9 | Maintains | Overweight | Get Alert |
| 01/07/2022 | Buy Now | 509.14% | Cantor Fitzgerald | Brian Cheng | → $24 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Poseida Therapeutics (PSTX) stock?
The latest price target for Poseida Therapeutics (NASDAQ:PSTX) was reported by HC Wainwright & Co. on July 25, 2024. The analyst firm set a price target for $20.00 expecting PSTX to rise to within 12 months (a possible 407.61% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Poseida Therapeutics (PSTX)?
The latest analyst rating for Poseida Therapeutics (NASDAQ:PSTX) was provided by HC Wainwright & Co., and Poseida Therapeutics reiterated their buy rating.
When was the last upgrade for Poseida Therapeutics (PSTX)?
There is no last upgrade for Poseida Therapeutics
When was the last downgrade for Poseida Therapeutics (PSTX)?
There is no last downgrade for Poseida Therapeutics.
When is the next analyst rating going to be posted or updated for Poseida Therapeutics (PSTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Poseida Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Poseida Therapeutics was filed on July 25, 2024 so you should expect the next rating to be made available sometime around July 25, 2025.
Is the Analyst Rating Poseida Therapeutics (PSTX) correct?
While ratings are subjective and will change, the latest Poseida Therapeutics (PSTX) rating was a reiterated with a price target of $20.00 to $20.00. The current price Poseida Therapeutics (PSTX) is trading at is $3.94, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.